Avera Pharmaceutical

The firm successfully raised a total of $72 million over three funding rounds, beginning with a $16 million Series A in May 2002 and culminating in a $48 million Series C in August 2004. This final round was led by Perseus-Soros BioPharmaceutical Fund and included participation from notable investors such as Frazier Healthcare Partners, Bay City Capital, and InterWest Partners. Following this financing, Steven A. Elms and Dr. Lutz Giebel joined the board of directors.

Avera's development pipeline included several clinical-stage assets licensed from major pharmaceutical companies like Novartis, Eli Lilly, and GlaxoSmithKline. Its lead product candidate, AV965, was in Phase 1 trials for treating cognitive impairment associated with schizophrenia and Alzheimer's dementia. The portfolio also featured gantacurium, a neuromuscular blocking agent intended for use in general anesthesia, and AV810 for the treatment of overactive bladder and irritable bowel syndrome. Jeffrey F. McKelvy was the founding President and CEO, later transitioning to the role of President and Chief Technical Officer in 2006 with the appointment of Dinu Sen as the new CEO. Despite its promising pipeline and significant funding, the company is now considered deadpooled. Keywords: Avera Pharmaceutical, neuroscience therapeutics, central nervous system drugs, CNS disorders, small-molecule drugs, clinical development, venture financing, Alzheimer's treatment, schizophrenia treatment, AV965, gantacurium, neuromuscular blocker, Jeffrey F. McKelvy, Dinu Sen, InterWest Partners, Frazier Healthcare Partners, Bay City Capital, Perseus-Soros, San Diego biotech, pharmaceutical development